Nanoparticle-assisted combination therapies for effective cancer treatment.

Combination chemotherapy and nanoparticle drug delivery are two areas that have shown significant promise in cancer treatment. Combined therapy of two or more drugs promotes synergism among the different drugs against cancer cells and suppresses drug resistance through distinct mechanisms of action. Nanoparticle drug delivery, on the other hand, enhances therapeutic effectiveness and reduces side effects of the drug payloads by improving their pharmacokinetics. These two active research fields have been recently merged to further improve the efficacy of cancer therapeutics. This review article summarizes the recent efforts in developing nanoparticle platforms to concurrently deliver multiple types of drugs for combination chemotherapy. We also highlight the challenges and design specifications that need to be considered in optimizing nanoparticle-based combination chemotherapy.

[1]  Gigi N. C. Chiu,et al.  Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment , 2010, Anti-cancer drugs.

[2]  T. Park,et al.  Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. , 2010, Biomaterials.

[3]  Chun-Ming Huang,et al.  Development of nanoparticles for antimicrobial drug delivery. , 2010, Current medicinal chemistry.

[4]  Liangfang Zhang,et al.  Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. , 2010, ACS nano.

[5]  Min Zhang,et al.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. , 2009, Small.

[6]  Li Tang,et al.  Controlled formulation of doxorubicin-polylactide nanoconjugates for cancer drug delivery , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[7]  María J. Vicent,et al.  Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.

[8]  S. Gong,et al.  Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers , 2009 .

[9]  Zheng-Rong Lu,et al.  Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. , 2009, Biomaterials.

[10]  Liangfang Zhang,et al.  Therapeutic nanoparticles to combat cancer drug resistance. , 2009, Current drug metabolism.

[11]  L. Mayer,et al.  Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo , 2009, Molecular Cancer Therapeutics.

[12]  K. Ulbrich,et al.  Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.

[13]  Xiangrong Song,et al.  Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  N. K. Jain,et al.  Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics , 2009, Journal of microencapsulation.

[15]  S. Ganta,et al.  Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. , 2009, Molecular pharmaceutics.

[16]  Jianjun Cheng,et al.  Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles. , 2009, Journal of the American Chemical Society.

[17]  K. Gelmon,et al.  Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[18]  Dar-Bin Shieh,et al.  Targeted Paclitaxel by conjugation to iron oxide and gold nanoparticles. , 2009, Journal of the American Chemical Society.

[19]  A. Wu,et al.  Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.

[20]  Lawrence Mayer,et al.  In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.

[21]  Susan E. Abbatiello,et al.  Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.

[22]  Stanislaus S. Wong,et al.  Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. , 2008, Journal of the American Chemical Society.

[23]  Ze Lu,et al.  Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.

[24]  T. Minko,et al.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. , 2008, Nanomedicine.

[25]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[26]  Jianjun Cheng,et al.  Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. , 2008, Angewandte Chemie.

[27]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[28]  D. Lim,et al.  Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis. , 2008, Bioorganic & medicinal chemistry.

[29]  N. K. Jain,et al.  Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. , 2008, Journal of drug targeting.

[30]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[31]  G. Kwon,et al.  Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[33]  E. Zubarev,et al.  Paclitaxel-functionalized gold nanoparticles. , 2007, Journal of the American Chemical Society.

[34]  J. Au,et al.  Tumor Priming Enhances Delivery and Efficacy of Nanomedicines , 2007, Journal of Pharmacology and Experimental Therapeutics.

[35]  H. Dai,et al.  Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. , 2007, Journal of the American Chemical Society.

[36]  L. Mayer,et al.  Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. , 2006, Oncology research.

[37]  Xiaogang Pan,et al.  Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[38]  Ho Sup Yoon,et al.  Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.

[39]  M. Bally,et al.  Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.

[40]  P. Couvreur,et al.  Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.

[41]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  F. Journé,et al.  Sequence-dependent synergistic effects of ibandronate in combination with antiestrogens on growth inhibition of estrogen receptor-positive breast cancer cells , 2006 .

[43]  P. Ellis,et al.  Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Shiladitya Sengupta,et al.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.

[45]  M. Paul,et al.  6-Mercaptopurine and Daunorubicin Double Drug Liposomes—Preparation, Drug-Drug Interaction and Characterization , 2005, Journal of liposome research.

[46]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[47]  Jinha M. Park,et al.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.

[48]  Jeffrey S. Johnston,et al.  Synergy Between 3′Azido-3′deoxythymidine and Paclitaxel in Human Pharynx FaDu Cells , 2003, Pharmaceutical Research.

[49]  A. Katz,et al.  Maladaptive Growth in the Failing Heart: The Cardiomyopathy of Overload , 2002, Cardiovascular Drugs and Therapy.

[50]  Vincristine liposomal--INEX: lipid-encapsulated vincristine, onco TCS, transmembrane carrier system--vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI. , 2004, Drugs in R&D.

[51]  M. Gilbert,et al.  An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis , 2004, Journal of Neuro-Oncology.

[52]  Kenneth K. Chan,et al.  Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome) , 2004, Investigational New Drugs.

[53]  D. Hossfeld,et al.  Effects of verapamil on the pharmacokinetics and metabolism of epirubicin , 2004, Cancer Chemotherapy and Pharmacology.

[54]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[55]  M. Gottesman Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[56]  D. Montaudon,et al.  Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants , 2001, British Journal of Cancer.

[57]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[58]  J. Blay,et al.  Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. , 2001, European journal of cancer.

[59]  Y. Rustum,et al.  Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. , 2000, Cancer research.

[60]  D. Pode,et al.  Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer , 2000, Anti-cancer drugs.

[61]  T. Lawrence,et al.  Interaction between gemcitabine and mitomycin-C in vitro , 2000, Cancer Chemotherapy and Pharmacology.

[62]  P Couvreur,et al.  Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.

[63]  L. Recht,et al.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  F. Kratz,et al.  Drug-polymer conjugates containing acid-cleavable bonds. , 1999, Critical reviews in therapeutic drug carrier systems.

[65]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[67]  B. Tromberg,et al.  Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. , 1996, Cancer research.

[68]  J. Rousseau,et al.  PEG‐coated Poly(lactic acid) Nanoparticles for the Delivery of Hexadecafluoro Zinc Phthalocyanine to EMT‐6 Mouse Mammary Tumours , 1995, The Journal of pharmacy and pharmacology.

[69]  D. Bazile,et al.  Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.

[70]  M. Hashida,et al.  Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. , 1995, Critical reviews in oncology/hematology.

[71]  David Putnam,et al.  Polymer conjugates with anticancer activity , 1995 .

[72]  R. Dorr,et al.  The effect of anticancer drug sequence in experimental combination chemotherapy. , 1993, Cancer investigation.

[73]  T. Miller,et al.  Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. , 1991, Journal of the National Cancer Institute.

[74]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[75]  F. Szoka,et al.  Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.

[76]  D. J. Adamson,et al.  Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. , 1975, Cancer research.

[77]  A. Bangham,et al.  Single bilayer liposomes. , 1971, Biochimica et biophysica acta.

[78]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.